{"title":"Kurukulasuriya等人(2017)关于IBD疫苗对肉鸡加拿大变异IBDV株有效性的论文答疑","authors":"","doi":"10.33140/jcei/03/01/00003","DOIUrl":null,"url":null,"abstract":"Kurukulasuriya, et al. (2017) are reporting the efficacy of two IBD vaccines against an early (6 days post-hatch) challenge\nwith a variant Canadian IBDV strain in broilers. A modified live vaccine(UNIVAX BD) administered by SQ route at 1 dayof-age delayed infection whereas an HVT-IBD vector vaccine (VAXXITEK HVT+IBD) administered in ovodid not protect.\nFurthermore, the authors suggested that the HVT-IBD vector induced immunosuppression responsible for an earlier IBDV\nchallenge strain replication in the bursa.\nThe data presented in the paper showed no evidence of VAXXITEK HVT+IBD vaccine take since the mean IBD ELISA\nantibody titer at D35 in the vaccinated/non-challenged group was not significantly different from that of the non-vaccinated\ngroup. It wasmuch lower than the expected one based on previous studies performed in the same conditions : in ovo\nvaccination of broilers [1,2]. Since there is no evidence of vaccine take, the other potential effects (immunosuppression and\nearlier IBDV replication in the bursa) observed in that group cannot be attributed to the vaccine.\nSince its launch in 2006 in Brazil, VAXXITEK HVT+IBD has been licensed in more than 75 countries and more than 80\nbillion birds have been vaccinated. VAXXITEK HVT+IBD is protecting against a wide variety of IBDV strains including\nthe classical, the very virulent and different variant strains. To our knowledge, noabsence of efficacy nor bursa depletions\nhave been so far officially reported as long as the vaccine has been administered properlyto healthy embryonated eggs or\nto healthy one-day-old chicks.","PeriodicalId":73657,"journal":{"name":"Journal of clinical & experimental immunology","volume":"40 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Q&A on the Paper of Kurukulasuriya et al. (2017) on IBD Vaccine Efficacy Against\\na Canadian Variant IBDV Strain in Broiler Chickens\",\"authors\":\"\",\"doi\":\"10.33140/jcei/03/01/00003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Kurukulasuriya, et al. (2017) are reporting the efficacy of two IBD vaccines against an early (6 days post-hatch) challenge\\nwith a variant Canadian IBDV strain in broilers. A modified live vaccine(UNIVAX BD) administered by SQ route at 1 dayof-age delayed infection whereas an HVT-IBD vector vaccine (VAXXITEK HVT+IBD) administered in ovodid not protect.\\nFurthermore, the authors suggested that the HVT-IBD vector induced immunosuppression responsible for an earlier IBDV\\nchallenge strain replication in the bursa.\\nThe data presented in the paper showed no evidence of VAXXITEK HVT+IBD vaccine take since the mean IBD ELISA\\nantibody titer at D35 in the vaccinated/non-challenged group was not significantly different from that of the non-vaccinated\\ngroup. It wasmuch lower than the expected one based on previous studies performed in the same conditions : in ovo\\nvaccination of broilers [1,2]. Since there is no evidence of vaccine take, the other potential effects (immunosuppression and\\nearlier IBDV replication in the bursa) observed in that group cannot be attributed to the vaccine.\\nSince its launch in 2006 in Brazil, VAXXITEK HVT+IBD has been licensed in more than 75 countries and more than 80\\nbillion birds have been vaccinated. VAXXITEK HVT+IBD is protecting against a wide variety of IBDV strains including\\nthe classical, the very virulent and different variant strains. To our knowledge, noabsence of efficacy nor bursa depletions\\nhave been so far officially reported as long as the vaccine has been administered properlyto healthy embryonated eggs or\\nto healthy one-day-old chicks.\",\"PeriodicalId\":73657,\"journal\":{\"name\":\"Journal of clinical & experimental immunology\",\"volume\":\"40 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-06-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of clinical & experimental immunology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33140/jcei/03/01/00003\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical & experimental immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33140/jcei/03/01/00003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Q&A on the Paper of Kurukulasuriya et al. (2017) on IBD Vaccine Efficacy Against
a Canadian Variant IBDV Strain in Broiler Chickens
Kurukulasuriya, et al. (2017) are reporting the efficacy of two IBD vaccines against an early (6 days post-hatch) challenge
with a variant Canadian IBDV strain in broilers. A modified live vaccine(UNIVAX BD) administered by SQ route at 1 dayof-age delayed infection whereas an HVT-IBD vector vaccine (VAXXITEK HVT+IBD) administered in ovodid not protect.
Furthermore, the authors suggested that the HVT-IBD vector induced immunosuppression responsible for an earlier IBDV
challenge strain replication in the bursa.
The data presented in the paper showed no evidence of VAXXITEK HVT+IBD vaccine take since the mean IBD ELISA
antibody titer at D35 in the vaccinated/non-challenged group was not significantly different from that of the non-vaccinated
group. It wasmuch lower than the expected one based on previous studies performed in the same conditions : in ovo
vaccination of broilers [1,2]. Since there is no evidence of vaccine take, the other potential effects (immunosuppression and
earlier IBDV replication in the bursa) observed in that group cannot be attributed to the vaccine.
Since its launch in 2006 in Brazil, VAXXITEK HVT+IBD has been licensed in more than 75 countries and more than 80
billion birds have been vaccinated. VAXXITEK HVT+IBD is protecting against a wide variety of IBDV strains including
the classical, the very virulent and different variant strains. To our knowledge, noabsence of efficacy nor bursa depletions
have been so far officially reported as long as the vaccine has been administered properlyto healthy embryonated eggs or
to healthy one-day-old chicks.